Gilead Sciences ($GILD) is giving GlobeImmune an undisclosed upfront payment for early development and funding to support continued development of its hepatitis B virus (HBV) therapeutic vaccine program. The two developers have inked a worldwide license and collaboration agreement for vaccine products for use in conjunction with Gilead's Viread, which is indicated to treat HIV/AIDS, and other oral therapies for the treatment of chronic HBV infection. Release